Functional genotype-phenotype associations in recessive dystrophic epidermolysis bullosa.

Background: Genotype-phenotype associations in recessive dystrophic epidermolysis bullosa (RDEB) have been difficult to elucidate.
Objective: To investigate RDEB genotype-phenotype associations and explore a functional approach to genotype classification.
Methods: Clinical examination and genetic testing of RDEB subjects, including assessment of clinical disease by RDEB subtype and extent of blistering. Genotypes were evaluated according to each variant's effect on type VII collagen function per updated literature and subsequently categorized by degree of impact on VII collagen function as low-impact (splice/missense, missense/missense), medium-impact (premature termination codon [PTC]/missense, splice/splice), and high-impact (PTC/PTC, PTC/splice). Genotype-phenotype associations were investigated using Kruskal-Wallis and Fisher's exact tests, and age-adjusted regressions.
Results: Eighty-three participants were included. High-impact variants were associated with worse RDEB subtype and clinical disease, including increased prevalence of generalized blistering (55.6% for low-impact vs 72.7% medium-impact vs 90.4% high-impact variants, P = .002). In age-adjusted regressions, participants with high-impact variants had 40.8-fold greater odds of squamous cell carcinoma compared to low-impact variants (P = .02), and 5.7-fold greater odds of death compared to medium-impact variants (P = .05).
Limitations: Cross-sectional design.
Conclusion: Functional genotype categories may stratify RDEB severity; high-impact variants correlated with worse clinical outcomes. Further validation in larger cohorts is needed.
Competing Interests: Conflicts of interest Drs Tang and Marinkovich are investigators for clinical trials sponsored by Abeona Therapeutics, Inc, and Phoenix Tissue Repair. Dr Marinkovich is also an investigator for clinical trials sponsored by WINGS, Castle Creek Pharmaceuticals, and Krystal Biotech. Dr Gorell is a consultant for Krystal Biotech. Dr So, Dr Nazaroff, Dr Yenamandra, Author Harris, Dr Fulchand, Dr Eid, and Author Dolorito have no conflicts of interest to declare.
(Copyright © 2024. Published by Elsevier Inc.)